Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, et al. Genetic ancestry contributes to somatic mutations in lung cancers from Admixed Latin American populations. Cancer Discov. 2021;11(3):591–8.

Article  CAS  PubMed  Google Scholar 

Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, et al. p.G12C KRAS mutation prevalence in non-small cell lung cancer: contribution from interregional variability and population substructures among hispanics. Transl Oncol. 2022;15(1):101276.

Article  PubMed  Google Scholar 

Frost N, Griesinger F, Hoffmann H, Länger F, Nestle U, Schütte W, et al. Lung Cancer in Germany. J Thorac Oncol. 2022;17(6):742–50.

Article  PubMed  Google Scholar 

Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-Mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2021;27(8):2209–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8(7):822–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished efficacy of programmed Death-(Ligand)1 inhibition in STK11- and KEAP1-Mutant lung adenocarcinoma is affected by KRAS Mutation Status. J Thorac Oncol. 2022;17(3):399–410.

Article  CAS  PubMed  Google Scholar 

Scharpf RB, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, et al. Genomic landscapes and Hallmarks of Mutant RAS in Human cancers. Cancer Res. 2022;82(21):4058–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA approval Summary: Sotorasib for KRAS G12C-Mutated metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C inhibition with Sotorasib in Advanced Solid tumors. N Engl J Med. 2020;383(13):1207–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, et al. Adagrasib in Non-small-cell Lung Cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022;387(2):120–31.

Article  PubMed  Google Scholar 

Ou SI, Jänne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, et al. First-in-human phase I/IB dose-finding study of Adagrasib (MRTX849) in patients with Advanced KRAS(G12C) solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599(7886):679–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical Acquired Resistance to KRAS(G12C) inhibition through a Novel KRAS Switch-II Pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021;11(8):1913–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med. 2021;384(25):2382–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR et al. KRAS(G12C) inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal. 2019;12(583).

Rosell R, Aguilar A, Pedraz C, Chaib I. KRAS inhibitors, approved. Nat Cancer. 2021;2(12):1254–6.

Article  PubMed  Google Scholar 

Kim D, Xue JY, Lito P, Targeting. KRAS(G12C): from inhibitory mechanism to modulation of Antitumor effects in patients. Cell. 2020;183(4):850–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCormick F. Sticking it to KRAS: covalent inhibitors enter the clinic. Cancer Cell. 2020;37(1):3–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward Therapeutic susceptibility of KRAS-Mutant cancers in Mouse models and patients. Cancer Discov. 2020;10(1):54–71.

Article  CAS  PubMed  Google Scholar 

Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65(4):1479–88.

Article  CAS  PubMed  Google Scholar 

Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, et al. Enhanced MET translation and signaling sustains K-Ras-driven proliferation under Anchorage-Independent Growth conditions. Cancer Res. 2015;75(14):2851–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crino L, et al. Selumetinib Plus Docetaxel compared with Docetaxel alone and progression-free survival in patients with KRAS-Mutant Advanced Non-small Cell Lung Cancer: the SELECT-1 Randomized Clinical Trial. JAMA. 2017;317(18):1844–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, et al. Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res. 2016;14(10):1019–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702–13.

Article  CAS  PubMed  Google Scholar 

Totani H, Shinjo K, Suzuki M, Katsushima K, Mase S, Masaki A, et al. Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma. Oncogene. 2020;39(35):5782–94.

Article  CAS  PubMed  Google Scholar 

Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, et al. Inhibiting fatty acid synthase with omeprazole to improve efficacy of Neoadjuvant Chemotherapy in patients with operable TNBC. Clin Cancer Res. 2021;27(21):5810–7.

Article  CAS  PubMed  Google Scholar 

Wu HC, Rérolle D, Berthier C, Hleihel R, Sakamoto T, Quentin S, et al. Actinomycin D targets NPM1c-Primed Mitochondria to restore PML-Driven senescence in AML Therapy. Cancer Discov. 2021;11(12):3198–213.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577(7790):421–5.